Aiding data retrieval in clinical trials with large language models: The APOLLO 11 Consortium in advanced lung cancer patients.

F Federica Corso (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) L Laura Mazzeo (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) V Vittoria Peppoloni (Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, Milan, Italy) G Giuseppe Leone (2Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy) V Vanja Miscovic (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) I Isabella Wiest (Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany) C Cecilia Silvestri (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) M Mario Occhipinti M Marta Brambilla T Teresa Beninato (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) A Alberto Ferrarin (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) M Marco Meazza Prina (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) C Claudia Proto (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) P Paolo Baili (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) M Monica Ganzinelli (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy) F Filippo Guglielmo Maria De Braud (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) G Giuseppe Lo Russo (Dipartimento Oncologia Toraco-Polmonare, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy) J Jakob Nikolas Kather A Alessandra Pedrocchi A Arsela Prelaj (1Fondazione IRCCS Istituto Nazionale dei Tumori and Politecnico di Milano, Milano, Italy)

Abstract

e23161 Background: Data retrieval is challenging in clinical research and traditional methods for data collection are often time-consuming and may be error-prone. Large Language Models (LLMs) have shown zero-shot capabilities in converting unstructured clinical text into structured data. These technologies could support the retrieval stage of clinical trials by leveraging the information reported in Electronic Health Records (EHRs) without relying any longer on manual curation. APOLLO 11 Consortium (NCT05550961) is a multicentric Italian trial which leverages a federated infrastructure for the analysis of advanced lung cancer patient data across Italy. Methods: We conducted a pilot study using Llama 3.1 8B on 358 Non-Small Cell Lung Cancer patients from the IRCCS Istituto Nazionale dei Tumori, leader of the APOLLO 11 Consortium. Anonymized EHRs have been analyzed within the LLM pipeline for feature extraction by Wiest et al. A combination of zero/few shot prompting techniques both in English and Italian languages was used. We selected smoking, histology, PD-L1 and staging as multiclass variables and bone/brain/liver metastases as binary variables. The ground truth collection involved a first Manual Data Entry (1-MDE) and a final full-revised MDE (2-MDE). The LLM accuracy was calculated only for the comparison LLM vs 2-MDE. In addition, we calculated the percentage of Missing Information (% MI) in 1-MDE, 2-MDE and LLM extraction. Results: Compared to 2-MDE, LLM achieved feature-specific accuracies of 0.78 for PD-L1, 0.85 for BONE METASTASIS, 0.83 for BRAIN METASTASIS, 0.89 for LIVER METASTASIS and 0.96 for TUMOUR STAGING. For smoking and staging, LLM extraction also reduced % MI relative to 1-MDE (Table 1). Only for PD-L1, we further analyzed the 12.8% of MI and found that 91.3% resulted from hallucinations (i.e., PD-L1 was misclassified as missing). Evaluations using English prompts confirmed the pipeline’s adaptability and high tasks accuracy. Conclusions: This study confirms the feasibility of LLMs for data retrieval in clinical trials demonstrating strong performance across diverse clinical features with minimal prompt optimization. LLMs could assist clinicians and data entry personnel in the 1-MDE process, streamlining initial data structuring and saving time. The 2-MDE step can remain as a quality check to address any discrepancies. Further improvements could focus on prompt optimization and integrating human feedback to reduce hallucination rates. Clinical trial information: NCT05550961 . %MI in 1-MDE, 2-MDE and LLM extraction. Accuracy refers only to LLM vs 2-MDE. Histology and metastasis sites were collected only in 2-MDE. NA = not available. Smoking PD-L1 Histology Bone Met Brain Met Liver Met T N M Stage % MI 1-MDE 6.4 8.9 NA NA NA NA 22.5 22.5 23.11 98.3 % MI 2-MDE 6.6 3 0 0 0 0 0 0 0 0 % MI LLM 2.7 12.8 10.3 0 0 0 0 0 0 6.9 % accuracy (LLM vs 2-MDE) 67 78 91 85 83 89 39 52 70 96

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

F

Federica Corso

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

L

Laura Mazzeo

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

V

Vittoria Peppoloni

Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, Milan, Italy

G

Giuseppe Leone

2Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Rome, Italy

V

Vanja Miscovic

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

I

Isabella Wiest

Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

C

Cecilia Silvestri

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

M

Mario Occhipinti

M

Marta Brambilla

T

Teresa Beninato

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

A

Alberto Ferrarin

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

M

Marco Meazza Prina

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

C

Claudia Proto

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

P

Paolo Baili

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

M

Monica Ganzinelli

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

F

Filippo Guglielmo Maria De Braud

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

G

Giuseppe Lo Russo

Dipartimento Oncologia Toraco-Polmonare, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy

J

Jakob Nikolas Kather

A

Alessandra Pedrocchi

A

Arsela Prelaj

1Fondazione IRCCS Istituto Nazionale dei Tumori and Politecnico di Milano, Milano, Italy